Search

Your search keyword '"Minhas A"' showing total 15,571 results
Start Over Author "Minhas A"
15,571 results on '"Minhas A"'

112. TandaPay Whistleblowing Communities: Shifting Workplace Culture Towards Zero-Tolerance Sexual Harassment Policies

Author

Davis, Joshua, Minhas, Rashid, Casario, Michelle, Bentley, William, Cosby, Kevin, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, and Arai, Kohei, editor

Published
2024
Full Text
View/download PDF

114. Lymphatic System in Pancreas

Author

Tiwari, Gaurav, Soni, Shankar Lal, Minhas, P. S., Dhas, Namdev, Tiwari, Ruchi, Dhas, Namdev, editor, Patel, Jayvadan K., editor, and Pathak, Yashwant V., editor

Published
2024
Full Text
View/download PDF

115. Simulation of Gasification Parameters Using Phenomenological Study for MSW Feedstock Based on Plasma Technique: A Review

Author

Minhas, Aman, Banshtu, R. S., Ghosh, Arindam, Series Editor, Chua, Daniel, Series Editor, de Souza, Flavio Leandro, Series Editor, Aktas, Oral Cenk, Series Editor, Han, Yafang, Series Editor, Gong, Jianghong, Series Editor, Jawaid, Mohammad, Series Editor, Sahu, Rina, editor, Prasad, Ranjit, editor, and Sahoo, K. L., editor

Published
2024
Full Text
View/download PDF

129. Mitosis Detection, Fast and Slow: Robust and Efficient Detection of Mitotic Figures

Author

Jahanifar, Mostafa, Shephard, Adam, Zamanitajeddin, Neda, Graham, Simon, Raza, Shan E Ahmed, Minhas, Fayyaz, and Rajpoot, Nasir

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

Counting of mitotic figures is a fundamental step in grading and prognostication of several cancers. However, manual mitosis counting is tedious and time-consuming. In addition, variation in the appearance of mitotic figures causes a high degree of discordance among pathologists. With advances in deep learning models, several automatic mitosis detection algorithms have been proposed but they are sensitive to {\em domain shift} often seen in histology images. We propose a robust and efficient two-stage mitosis detection framework, which comprises mitosis candidate segmentation ({\em Detecting Fast}) and candidate refinement ({\em Detecting Slow}) stages. The proposed candidate segmentation model, termed \textit{EUNet}, is fast and accurate due to its architectural design. EUNet can precisely segment candidates at a lower resolution to considerably speed up candidate detection. Candidates are then refined using a deeper classifier network, EfficientNet-B7, in the second stage. We make sure both stages are robust against domain shift by incorporating domain generalization methods. We demonstrate state-of-the-art performance and generalizability of the proposed model on the three largest publicly available mitosis datasets, winning the two mitosis domain generalization challenge contests (MIDOG21 and MIDOG22). Finally, we showcase the utility of the proposed algorithm by processing the TCGA breast cancer cohort (1,125 whole-slide images) to generate and release a repository of more than 620K mitotic figures., Comment: Extended version of the work done for MIDOG challenge submission

Published
2022

130. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.

Author

Cheema, Huzaifa, Shafiee, Arman, Athar, Mohammad, Rafiei, Mohammad, Mehmannavaz, Atefe, Jafarabady, Kyana, Shahid, Abia, Ahmad, Adeel, Ijaz, Sardar, Dani, Sourbha, Minhas, Abdul, Nashwan, Abdulqadir, Fudim, Marat, and Fonarow, Gregg

Subjects
HFPEF, SGLT2I, dapagliflozin, empagliflozin, heart failure
Abstract

AIMS: We sought to conduct a meta-analysis to evaluate the efficacy and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure (HF) with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF). METHODS: We searched the Cochrane Library, MEDLINE (via PubMed), Embase, and ClinicalTrials.gov till March 2023 to retrieve all randomized controlled trials of SGLT2i in patients with HFpEF or HFmrEF. Risk ratios (RRs) and standardized mean differences (SMDs) with their 95% confidence intervals (95% CIs) were pooled using a random-effects model. RESULTS: We included data from 14 RCTs. SGLT2i reduced the risk of the primary composite endpoint of first HF hospitalization or cardiovascular death (RR 0.81, 95% CI: 0.76, 0.87; I2 = 0%); these results were consistent across the cohorts of HFmrEF and HFpEF patients. There was no significant decrease in the risk of cardiovascular death (RR 0.96, 95% CI: 0.82, 1.13; I2 = 36%) and all-cause mortality (RR 0.97, 95% CI: 0.89, 1.05; I2 = 0%). There was a significant improvement in the quality of life in the SGLT2i group (SMD 0.13, 95% CI: 0.06, 0.20; I2 = 51%). CONCLUSION: The use of SGLT2i is associated with a lower risk of the primary composite outcome and a higher quality of life among HFpEF/HFmrEF patients. However, further research involving more extended follow-up periods is required to draw a comprehensive conclusion. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD42022364223).

Published
2023

131. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study

Author

Boerwinkle, Anna H, Gordon, Brian A, Wisch, Julie, Flores, Shaney, Henson, Rachel L, Butt, Omar H, McKay, Nicole, Chen, Charles D, Benzinger, Tammie LS, Fagan, Anne M, Handen, Benjamin L, Christian, Bradley T, Head, Elizabeth, Mapstone, Mark, Rafii, Michael S, O'Bryant, Sid, Lai, Florence, Rosas, H Diana, Lee, Joseph H, Silverman, Wayne, Brickman, Adam M, Chhatwal, Jasmeer P, Cruchaga, Carlos, Perrin, Richard J, Xiong, Chengjie, Hassenstab, Jason, McDade, Eric, Bateman, Randall J, Ances, Beau M, Syndrome, Alzheimer's Biomarker Consortium-Down, Aizenstein, Howard J, Andrews, Howard F, Bell, Karen, Birn, Rasmus M, Bulova, Peter, Cheema, Amrita, Chen, Kewei, Clare, Isabel, Clark, Lorraine, Cohen, Ann D, Constantino, John N, Doran, Eric W, Feingold, Eleanor, Foroud, Tatiana M, Hartley, Sigan L, Hom, Christy, Honig, Lawrence, Ikonomovic, Milos D, Johnson, Sterling C, Jordan, Courtney, Kamboh, M Ilyas, Keator, David, Klunk, William E, Kofler, Julia K, Kreisl, William C, McHale, Sharon J Krinsky-, Lao, Patrick, Laymon, Charles, Lott, Ira T, Lupson, Victoria, Mathis, Chester A, Minhas, Davneet S, Nadkarni, Neelesh, Pang, Deborah, Petersen, Melissa, Price, Julie C, Pulsifer, Margaret, Reiman, Eric, Rizvi, Batool, Sabbagh, Marwan N, Schupf, Nicole, Tudorascu, Dana L, Tumuluru, Rameshwari, Tycko, Benjamin, Varadarajan, Badri, White, Desiree A, Yassa, Michael A, Zaman, Shahid, Zhang, Fan, Network, Dominantly Inherited Alzheimer, Adams, Sarah, Allegri, Ricardo, Araki, Aki, Barthelemy, Nicolas, Bechara, Jacob, Berman, Sarah, Bodge, Courtney, Brandon, Susan, Brooks, William, Brosch, Jared, Buck, Jill, Buckles, Virginia, Carter, Kathleen, Cash, Lisa, Mendez, Patricio C, Chua, Jasmin, Chui, Helena, Courtney, Laura, Day, Gregory, and DeLaCruz, Chrismary

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Brain Disorders, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Dementia, Neurodegenerative, Intellectual and Developmental Disabilities (IDD), Genetics, Acquired Cognitive Impairment, Alzheimer's Disease, Down Syndrome, Prevention, Aging, Biomedical Imaging, Clinical Research, 2.1 Biological and endogenous factors, Neurological, Adult, Aged, Humans, Middle Aged, Alzheimer Disease, Amyloid beta-Peptides, Apolipoproteins E, Biomarkers, Cross-Sectional Studies, Positron-Emission Tomography, Cerebral Cortex, Alzheimer's Biomarker Consortium-Down Syndrome, Dominantly Inherited Alzheimer Network, Neurology & Neurosurgery, Clinical sciences
Abstract

BackgroundImportant insights into the early pathogenesis of Alzheimer's disease can be provided by studies of autosomal dominant Alzheimer's disease and Down syndrome. However, it is unclear whether the timing and spatial distribution of amyloid accumulation differs between people with autosomal dominant Alzheimer's disease and those with Down syndrome. We aimed to directly compare amyloid changes between these two groups of people.MethodsIn this cross-sectional study, we included participants (aged ≥25 years) with Down syndrome and sibling controls who had MRI and amyloid PET scans in the first data release (January, 2020) of the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study. We also included carriers of autosomal dominant Alzheimer's disease genetic mutations and non-carrier familial controls who were within a similar age range to ABC-DS participants (25-73 years) and had MRI and amyloid PET scans at the time of a data freeze (December, 2020) of the Dominantly Inherited Alzheimer Network (DIAN) study. Controls from the two studies were combined into a single group. All DIAN study participants had genetic testing to determine PSEN1, PSEN2, or APP mutation status. APOE genotype was determined from blood samples. CSF samples were collected in a subset of ABC-DS and DIAN participants and the ratio of amyloid β42 (Aβ42) to Aβ40 (Aβ42/40) was measured to evaluate its Spearman's correlation with amyloid PET. Global PET amyloid burden was compared with regards to cognitive status, APOE ɛ4 status, sex, age, and estimated years to symptom onset. We further analysed amyloid PET deposition by autosomal dominant mutation type. We also assessed regional patterns of amyloid accumulation by estimated number of years to symptom onset. Within a subset of participants the relationship between amyloid PET and CSF Aβ42/40 was evaluated.Findings192 individuals with Down syndrome and 33 sibling controls from the ABC-DS study and 265 carriers of autosomal dominant Alzheimer's disease mutations and 169 non-carrier familial controls from the DIAN study were included in our analyses. PET amyloid centiloid and CSF Aβ42/40 were negatively correlated in carriers of autosomal dominant Alzheimer's disease mutations (n=216; r=-0·565; p

Published
2023

132. Timing of Alzheimers Disease by Intellectual Disability Level in Down Syndrome.

Author

Hartley, Sigan, Fleming, Victoria, Schworer, Emily, Peven, Jamie, Handen, Benjamin, Krinsky-McHale, Sharon, Lee, Laisze, Tudorascu, Dana, Laymon, Charles, Minhas, Davneet, Luo, Weiquan, Cohen, Annie, Zaman, Shahid, Ances, Beau, Lai, Florence, Rosas, H, Klunk, William, Christian, Bradley, Head, Elizabeth, Hom, Christy, and Mapstone, Mark

Subjects
Alzheimer’s disease, Down syndrome, amyloid, cognitive, dementia, imaging, intellectual, memory, tau, Humans, Alzheimer Disease, Down Syndrome, Intellectual Disability, Cognitive Dysfunction, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
Abstract

BACKGROUND: Trisomy 21 causes Down syndrome (DS) and is a recognized cause of early-onset Alzheimers disease (AD). OBJECTIVE: The current study sought to determine if premorbid intellectual disability level (ID) was associated with variability in age-trajectories of AD biomarkers and cognitive impairments. General linear mixed models compared the age-trajectory of the AD biomarkers PET Aβ and tau and cognitive decline across premorbid ID levels (mild, moderate, and severe/profound), in models controlling trisomy type, APOE status, biological sex, and site. METHODS: Analyses involved adults with DS from the Alzheimers Biomarkers Consortium-Down Syndrome. Participants completed measures of memory, mental status, and visuospatial ability. Premorbid ID level was based on IQ or mental age scores prior to dementia concerns. PET was acquired using [11C] PiB for Aβ, and [18F] AV-1451 for tau. RESULTS: Cognitive data was available for 361 participants with a mean age of 45.22 (SD = 9.92) and PET biomarker data was available for 154 participants. There was not a significant effect of premorbid ID level by age on cognitive outcomes. There was not a significant effect of premorbid ID by age on PET Aβ or on tau PET. There was not a significant difference in age at time of study visit of those with mild cognitive impairment-DS or dementia by premorbid ID level. CONCLUSION: Findings provide robust evidence of a similar time course in AD trajectory across premorbid ID levels, laying the groundwork for the inclusion of individuals with DS with a variety of IQ levels in clinical AD trials.

Published
2023

136. The impacts of the COVID-19 lockdowns on the work of academic staff at higher education institutions: an international assessment

Author

Leal Filho, Walter, Wall, Tony, Salvia, Amanda Lange, Vasconcelos, Claudio Ruy, Abubakar, Ismaila Rimi, Minhas, Aprajita, Mifsud, Mark, Kozlova, Valerija, Lovren, Violeta Orlovic, Azadi, Hossein, Sharifi, Ayyoob, Kovaleva, Marina, LeVasseur, Todd, Luetz, Johannes, Velazquez, Luis, Singh, Priyatma, Pretorius, Rudi, Akib, Noor Adelyna Mohammed, Savelyeva, Tamara, Brandli, Luciana, Muthu, Nandhivarman, and Lombardi, Patrizia

Published
2024
Full Text
View/download PDF

137. Frequency, morbidity and equity — the case for increased research on male fertility

Author

Kimmins, Sarah, Anderson, Richard A., Barratt, Christopher L. R., Behre, Hermann M., Catford, Sarah R., De Jonge, Christopher J., Delbes, Geraldine, Eisenberg, Michael L., Garrido, Nicolas, Houston, Brendan J., Jørgensen, Niels, Krausz, Csilla, Lismer, Ariane, McLachlan, Robert I., Minhas, Suks, Moss, Tim, Pacey, Allan, Priskorn, Lærke, Schlatt, Stefan, Trasler, Jacquetta, Trasande, Leonardo, Tüttelmann, Frank, Vazquez-Levin, Mónica Hebe, Veltman, Joris A., Zhang, Feng, and O’Bryan, Moira K.

Published
2024
Full Text
View/download PDF

138. Conservative and medical treatments of non-sickle cell disease-related ischemic priapism: a systematic review by the EAU Sexual and Reproductive Health Panel

Author

Capogrosso, Paolo, Dimitropolous, Kostas, Russo, Giorgio Ivan, Tharakan, Tharu, Milenkovic, Uros, Cocci, Andrea, Boeri, Luca, Gül, Murat, Bettocchi, Carlo, Carvalho, Joana, Kalkanlı, Arif, Corona, Giovanni, Hatzichristodoulou, Georgios, Jones, Hugh T., Kadioglu, Ates, Martinez-Salamanca, Juan Ignacio, Modgil, Vaibhav, Serefoglu, Ege Can, Verze, Paolo, Salonia, Andrea, and Minhas, Suks

Published
2024
Full Text
View/download PDF

139. Surgical and minimally invasive treatment of ischaemic and non-ischaemic priapism: a systematic review by the EAU Sexual and Reproductive Health Guidelines panel

Author

Milenkovic, U., Cocci, A., Veeratterapillay, R., Dimitropoulos, K., Boeri, L., Capogrosso, P., Cilesiz, N. C., Gul, M., Hatzichristodoulou, G., Modgil, V., Russo, G. I., Tharakan, T., Omar, M. I., Bettocchi, C., Carvalho, J., Yuhong, Y., Corona, G., Jones, H., Kadioglu, A., Martinez-Salamanca, J. I., Verze, P., Serefoglu, E. C., Minhas, S., and Salonia, A.

Published
2024
Full Text
View/download PDF

142. Lessons learned from replicating a study on information-retrieval based test case prioritization

Author

Minhas, Nasir Mehmood, Irshad, Mohsin, Petersen, Kai, and Börstler, Jürgen

Subjects
Computer Science - Software Engineering
Abstract

Objective: In this study, we aim to replicate an artefact-based study on software testing to address the gap. We focus on (a) providing a step by step guide of the replication, reflecting on challenges when replicating artefact-based testing research, (b) Evaluating the replicated study concerning its validity and robustness of the findings. Method: We replicate a test case prioritization technique by Kwon et al. We replicated the original study using four programs, two from the original study and two new programs. The replication study was implemented using Python to support future replications. Results: Various general factors facilitating replications are identified, such as: (1) the importance of documentation; (2) the need of assistance from the original authors; (3) issues in the maintenance of open source repositories (e.g., concerning needed software dependencies); (4) availability of scripts. We also raised several observations specific to the study and its context, such as insights from using different mutation tools and strategies for mutant generation. Conclusion: We conclude that the study by Kwon et al. is replicable for small and medium programs and could be automated to facilitate software practitioners, given the availability of required information., Comment: 22 pages, 3 figures, 6 tables

Published
2022

143. Neurovascular coupling methods in healthy individuals using transcranial doppler ultrasonography: A systematic review and consensus agreement

Author

Ball, James D, Hills, Eleanor, Altaf, Afzaa, Ramesh, Pranav, Green, Matthew, Surti, Farhaana BS, Minhas, Jatinder S, Robinson, Thompson G, Bond, Bert, Lester, Alice, Hoiland, Ryan, Klein, Timo, Liu, Jia, Nasr, Nathalie, Junejo, Rehan T, Müller, Martin, Lecchini-Visintini, Andrea, Mitsis, Georgios, Burma, Joel S, Smirl, Jonathan D, Pizzi, Michael A, Manquat, Elsa, Lucas, Samuel JE, Mullinger, Karen J, Mayhew, Steve, Bailey, Damian M, Rodrigues, Gabriel, Soares, Pedro Paulo, Phillips, Aaron A, Prokopiou, Prokopis C, and C Beishon, Lucy

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results